New anticoagulants for prevention of stroke in patients with atrial fibrillation

Juan F. Viles-Gonzalez, Valentin Fuster, Jonathan L. Halperin

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

New Anticoagulants in Atrial Fibrillation. Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using vitamin K antagonists (VKA) is currently prescribed for prevention of ischemic stroke in patients with AF. A narrow therapeutic range and frequent food and drug interactions underly the need for regular monitoring of anticoagulation intensity and impairs the utility and safety of VKA, stimulating a quest for alternative anticoagulant agents. Recently developed anticoagulants include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors rivaroxaban, apixaban, edoxaban, to name those in the most advanced stages of clinical development. This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF.

Original languageEnglish (US)
Pages (from-to)948-955
Number of pages8
JournalJournal of Cardiovascular Electrophysiology
Volume22
Issue number8
DOIs
StatePublished - Aug 1 2011

    Fingerprint

Keywords

  • anticoagulation
  • atrial fibrillation
  • dabigatran
  • factor Xa inhibitor
  • stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this